Dipartimento di Scienze Mediche e Chirurgiche, Clinica Neurologica, Università degli Studi di Brescia, Brescia, Italia (A. Pezzini, P.C., L.P., A.M., V.D.G., A. Padovani; Dipartimento di Scienze del Sistema Nervoso e del Comportamento, Unità di Statistica Medica e Genomica, Università di Pavia, Pavia, Italia (M.G.); Centro Trombosi, IRCCS Istituto Clinico Humanitas, Rozzano-Milano, Italia (C.L., P.F.); Stroke Unit, Azienda Ospedaliera Sant'Andrea, Roma, Italia (R.P., A.S., M.R.); Dipartimento di Neuroscienze, Riabilitazione, Oftalmologia, Genetica e Scienze Materno-Infantili, Università di Genova, Genova, Italia (C.G., D.M.); Stroke Unit, Clinica Neurologica, Nuovo Ospedale Civile "S. Agostino Estense", AUSL Modena, Italia (A.Z., A.M.S.); Unità di Neurologia, Ospedale di Circolo, Università dell'Insubria, Varese, Italia (M.L.D.); Stroke Unit, Divisione di Medicina Cardiovascolare, Università di Perugia, Perugia, Italia (M.P.); Unità di Neurologia, Ospedale S. Andrea, La Spezia, Italia (M.D.S.); U.O.C. Neurologia, A.O Universitaria "San Giovanni di Dio e Ruggi d'Aragona", Salerno, Italia (A.T.); Dipartimento di Neuroscienze, Scienze Psichiatriche e Anestesiologiche, Clinica Neurologica, Università di Messina, Messina, Italia (R.M.); Istituto di Ricovero e Cura a Carattere Scientifico, Centro Neurolesi Bonino-Pulejo, Messina, Italia (R.S.C.); UO Neurologia, Azienda Ospedaliera-Universitaria Borgo Trento, Verona, Italia (P.B.); Stroke Center, Dipartimento di Neurologia, Ospedale Sacro Cuore Negrar, Verona, Italia (A.A.); Stroke Unit, U.O Neurologia, Azienda Ospedaliera "C. Poma", Mantova, Italia (G.S.); Stroke Unit, U.O Neurologia, IRCCS Ospedale S. Raffaele, Milano, Italia (M.S., G.G.); U.C Malattie Cerebrovascolari e Stroke Unit (A.C.) and U.C Neurologia d'Urgenza (G.M.), IRCCS Fondazione Istituto Neurologico Nazionale "C. Mondino," Pavia, Italia; Neurologia d'Urgenza and Stroke Unit, IRCCS Istituto Clinico Humanitas, Rozzano-Milano, Italia (S.M.); Stroke Un
Circulation. 2014 Apr 22;129(16):1668-76. doi: 10.1161/CIRCULATIONAHA.113.005663. Epub 2014 Feb 7.
Data on long-term risk and predictors of recurrent thrombotic events after ischemic stroke at a young age are limited.
We followed 1867 patients with first-ever ischemic stroke who were 18 to 45 years of age (mean age, 36.8±7.1 years; women, 49.0%), as part of the Italian Project on Stroke in Young Adults (IPSYS). Median follow-up was 40 months (25th to 75th percentile, 53). The primary end point was a composite of ischemic stroke, transient ischemic attack, myocardial infarction, or other arterial events. One hundred sixty-three patients had recurrent thrombotic events (average rate, 2.26 per 100 person-years at risk). At 10 years, cumulative risk was 14.7% (95% confidence interval, 12.2%-17.9%) for primary end point, 14.0% (95% confidence interval, 11.4%-17.1%) for brain ischemia, and 0.7% (95% confidence interval, 0.4%-1.3%) for myocardial infarction or other arterial events. Familial history of stroke, migraine with aura, circulating antiphospholipid antibodies, discontinuation of antiplatelet and antihypertensive medications, and any increase of 1 traditional vascular risk factor were independent predictors of the composite end point in multivariable Cox proportional hazards analysis. A point-scoring system for each variable was generated by their β-coefficients, and a predictive score (IPSYS score) was calculated as the sum of the weighted scores. The area under the receiver operating characteristic curve of the 0- to 5-year score was 0.66 (95% confidence interval, 0.61-0.71; mean, 10-fold internally cross-validated area under the receiver operating characteristic curve, 0.65).
Among patients with ischemic stroke aged 18 to 45 years, the long-term risk of recurrent thrombotic events is associated with modifiable, age-specific risk factors. The IPSYS score may serve as a simple tool for risk estimation.
关于年轻患者发生缺血性卒中后复发性血栓栓塞事件的长期风险和预测因素的数据有限。
我们对 1867 名年龄在 18 至 45 岁(平均年龄为 36.8±7.1 岁;女性占 49.0%)的首发缺血性卒中患者进行了随访,这些患者为意大利青年卒中项目(IPSYS)的一部分。中位随访时间为 40 个月(25 至 75 百分位数,53 个月)。主要终点是缺血性卒中、短暂性脑缺血发作、心肌梗死或其他动脉事件的复合终点。163 例患者发生了复发性血栓栓塞事件(平均每 100 人年风险率为 2.26)。10 年时,主要终点的累积风险为 14.7%(95%置信区间,12.2%17.9%),脑缺血的累积风险为 14.0%(95%置信区间,11.4%17.1%),心肌梗死或其他动脉事件的累积风险为 0.7%(95%置信区间,0.4%1.3%)。卒中家族史、有先兆偏头痛、循环抗磷脂抗体、抗血小板和降压药物停药以及任何 1 种传统血管危险因素增加,是多变量 Cox 比例风险分析中复合终点的独立预测因素。通过其β系数为每个变量生成一个评分系统,并计算加权评分之和得到预测评分(IPSYS 评分)。0 至 5 年评分的受试者工作特征曲线下面积为 0.66(95%置信区间,0.610.71;内部 10 倍交叉验证的受试者工作特征曲线下平均面积,0.65)。
在年龄为 18 至 45 岁的缺血性卒中患者中,复发性血栓栓塞事件的长期风险与可改变的、年龄特异性的危险因素相关。IPSYS 评分可作为一种简单的风险评估工具。